Oxytocin vs PT-141
FDA Approved vs FDA Approved
monitor Mechanism-based · 60% Both Oxytocin and PT-141 can raise blood pressure. Monitor BP regularly and consider adding cardiovascular support (cardarine, telmisartan, or similar).
Molecular Data
Oxytocin PT-141
Weight 1,007.19 Da —
Half-life 3-6 minutes ~2.7 hours
Chain 9 amino acids —
Type Cyclic nonapeptide Melanocortin receptor agonist
Key Benefits
Oxytocin
01 FDA-approved for labor induction with precise dosing via IV
02 Immediate onset in obstetric settings
03 Established safety profile in clinical use
04 Researched for anxiety, PTSD, autism, sexual dysfunction
PT-141
01 FDA-approved pharmaceutical route
02 Predictable absorption profile
03 Effective for both male and female sexual dysfunction
04 Works within 45 minutes
05 Effective in PDE5 inhibitor-resistant cases
06 Central mechanism (not dependent on blood flow)
Dosing Protocols
Oxytocin
Intranasal: 20-24 IU; Injectable: 10-40 IU; Sublingual: 50-100 IU / As needed for social/sexual support, or 1-2x daily for anxiety/PTSD protocols; max 1 dose per 24hr for sexual function
Labor Induction 0.5-2 mU/min initial, titrate to 1-2 mU/min every 30-60 min Continuous IV infusion
Postpartum Hemorrhage Prevention 10 units IM or 10-40 units in IV solution Single dose after placental delivery
PT-141
Women: 1.75mg (FDA-approved); Men: 1-2mg; Start 0.5mg test dose for tolerance / As needed before sexual activity; max 1 dose per 24 hours
Female HSDD (FDA-approved) 1.75mg As needed, max 1 dose/24hr
Male Erectile Dysfunction 1-2mg As needed, 45-60min before activity
Female Arousal Disorder 0.75-1.25mg As needed, max 1 dose/24hr
Low Starting Dose 0.5mg Test dose for tolerance assessment
Side Effects
Oxytocin
Mild headache
Nasal irritation (intranasal)
Nausea or vomiting
Transient blood pressure changes
PT-141
Nausea (40%)
Flushing (20%)
Headache (11%)
Injection site reactions
Contraindications
Certain obstetric conditions (see prescribing info)
Pregnancy (without medical supervision)
Active sinus infection (intranasal)
Severe hyponatremia
Uncontrolled hypertension
Cardiovascular disease
Use of nitrate medications
Pregnancy or breastfeeding
Research Evidence
Oxytocin PT-141
Status FDA Approved FDA Approved
References 3 studies 4 studies
Latest — 2022
FDA Approved Yes Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.